Silence Therapeutics plc
SLN
$5.35
-$0.11-2.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.40M | 27.93M | 43.49M | 19.94M | 21.99M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.40M | 27.93M | 43.49M | 19.94M | 21.99M |
| Cost of Revenue | 6.01M | 9.26M | 12.01M | 11.18M | 9.61M |
| Gross Profit | 21.39M | 18.67M | 31.48M | 8.75M | 12.39M |
| SG&A Expenses | 26.88M | 28.76M | 27.71M | 26.11M | 25.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 95.95M | 96.87M | 89.78M | 79.20M | 68.00M |
| Operating Income | -68.55M | -68.94M | -46.30M | -59.26M | -46.01M |
| Income Before Tax | -75.78M | -67.96M | -41.50M | -69.09M | -43.35M |
| Income Tax Expenses | 4.92M | 5.13M | 5.38M | 5.60M | 6.64M |
| Earnings from Continuing Operations | -80.70 | -73.10 | -46.88 | -74.69 | -49.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.70M | -73.10M | -46.88M | -74.69M | -49.99M |
| EBIT | -68.55M | -68.94M | -46.30M | -59.26M | -46.01M |
| EBITDA | -67.97M | -68.35M | -45.69M | -58.67M | -45.41M |
| EPS Basic | -5.13 | -4.66 | -3.01 | -5.01 | -3.61 |
| Normalized Basic EPS | -0.99 | -0.90 | -0.56 | -0.94 | -0.65 |
| EPS Diluted | -5.13 | -4.66 | -3.01 | -5.01 | -3.61 |
| Normalized Diluted EPS | -0.99 | -0.90 | -0.56 | -0.94 | -0.65 |
| Average Basic Shares Outstanding | 188.75M | 188.26M | 184.99M | 176.68M | 166.92M |
| Average Diluted Shares Outstanding | 62.92M | 62.75M | 61.66M | 58.89M | 55.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |